This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zerbaxa

Merck & Co., Inc.

Drug Names(s): CXA-101/FK-037/FR264205 and tazobactam, CXA-201, CXA201, MK-7625A

Description: CXA-201 is an intravenously administered combination of CXA-101 and the ß-lactamase inhibitor tazobactam. CXA-201 is active against clinical strains of Pseudomonas aeruginosa (MIC50 <1 ug/mL), ceftazidime-resistant Escherichia coli (MIC50 1 ug/mL), ceftazidime-resistant Klebsiella pneumoniae (MIC50 4 ug/mL), ceftazidime-resistant indole positive Proteus spp. (MIC50 2 ug/mL), ESBL phenotype Proteus mirabilis strains (MIC50 1 ug.mL), Pseudomonas aeruginosa (MIC50 1 ug/mL), and Bacterioides fragilis strains (MIC50 1 ug/mL). Lesser activity is observed against ceftzidime-resistant Citrobacter spp. (MIC50 = 16 ug/mL) and ceftazidime-resistant Enterobacter spp. (MIC50 > 16 ug/mL).

Deal Structure: Calixa and Astellas
In November 2007, Calixa acquired the global development rights (except for certain Asia-Pacific territories) to CXA-101 from Astellas.

Calixa and Cubist
In December 2009, Cubist Pharmaceuticals agreed to acquire Calixa. On closing, Cubist will pay to the Calixa stockholders $92.5 million in cash, subject to certain adjustments, and Calixa will become a wholly-owned subsidiary of Cubist. Cubist also will be required to make potential payments to the Calixa stockholders of up to $310 million upon achieving certain development, regulatory, and commercial milestones related to products which incorporate CXA-101. The acquisition was also completed in December 2009.

Cubist and Astellas
In March 2013, Cubist and Astellas entered into an agreement under which Cubist obtains the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas. With the attainment of these rights, Cubist now owns worldwide...See full deal structure in Biomedtracker

Partners: Astellas Pharma, Inc.


Zerbaxa News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug